Theratechnologies Inc.

TH

CA88338H7040

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.8 ^CAD	0.00%		-0.55%	-15.89%

Apr. 10	Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision	MT
Apr. 10	Theratechnologies Up Near 6% In US Premarket As Q1 Net Loss Narrows, Accelerates Phase 1 Trial of Ovarian Cancer Drug	MT

Theratechnologies Inc. Reports Earnings Results for the Full Year Ended November 30, 2023

February 21, 2024 at 08:01 am EST

Theratechnologies Inc. reported earnings results for the full year ended November 30, 2023. For the full year, the company reported sales was USD 81.76 million compared to USD 80.06 million a year ago. Net loss was USD 23.96 million compared to USD 47.24 million a year ago.

Basic loss per share from continuing operations was USD 0.91 compared to USD 1.98 a year ago.

Latest news about Theratechnologies Inc.

Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision	Apr. 10	MT
Theratechnologies Up Near 6% In US Premarket As Q1 Net Loss Narrows, Accelerates Phase 1 Trial of Ovarian Cancer Drug	Apr. 10	MT
Transcript : Theratechnologies Inc., Q1 2024 Earnings Call, Apr 10, 2024	Apr. 10
Theratechnologies Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024	Apr. 10	CI
Theratechnologies Brief: Citing Acceleration of Phase 1 trial of sudocetaxel zendusortide in advanced ovarian cancer with enrollment of next cohort of patients underway at higher dose level	Apr. 10	MT
Theratechnologies Brief: FY2024 revenue guidance confirmed between US$87-$90 million and an Adjusted EBITDA in the range of $13-15 million	Apr. 10	MT
Theratechnologies Brief: Q1 2024 consolidated revenue of US$16.2 Million; Says Report marks third consecutive quarter of near-flat-to-positive Adjusted EBITDA	Apr. 10	MT
Theratechnologies Inc. Re-Affirms Earnings Guidance for the Fiscal Year 2024	Apr. 10	CI
North American Morning Briefing : Traders Await -2-	Apr. 10	DJ
Theratechnologies Inc. Preclinical Data Presentation At AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology? Oncology Platform	Apr. 08	CI
Theratechnologies Inc. Appoints Elina Tea to its Board of Directors and as Member of the Company's Audit Committee	Apr. 05	CI
Theratechnologies To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform	Mar. 28	MT
Theratechnologies Brief: To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform	Mar. 28	MT
Theratechnologies Inc. Announces That It Will Phase Down Its Preclinical Oncology Research Activities	Mar. 22	CI
Theratechnologies to Phase Down Preclinical Oncology Research Program	Mar. 22	MT
Theratechnologies to Wind Down Preclinical Research, Focus on Ovarian Cancer Study	Mar. 22	MT
Theratechnologies Inc. Appoints Jordan Zwick to Its Board of Directors and as Member of the Audit Committee	Mar. 21	CI
Theratechnologies Initiates Higher Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer	Mar. 21	MT
Theratechnologies Inc. Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer	Mar. 21	CI
Theratechnologies Inc. Announces Board Changes	Feb. 29	CI
Theratechnologies Down 30% In US Premarket -- Receives Refusal To File Letter From FDA	Feb. 27	MT
Theratechnologies Shares Sink Premarket After FDA Refusal to File Letter	Feb. 27	DJ
Theratechnologies Brief: Down 21% In US Premarket As Says Received Refusal To File Letter For Trogarzo Intramuscular Method Of Administration SBLA From FDA	Feb. 27	MT
Theratechnologies Inc. Receives Refusal to File Letter for Trogarzo Intramuscular Method of Administration sBLA from FDA	Feb. 27	CI
Transcript : Theratechnologies Inc., Q4 2023 Earnings Call, Feb 21, 2024	Feb. 21

Chart Theratechnologies Inc.

Duration

Period

More charts

Company Profile

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

Sector

Pharmaceuticals

Calendar

2024-05-09 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Theratechnologies Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.8 CAD

Average target price

8 CAD

Spread / Average Target

+344.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
THERATECHNOLOGIES INC.	-15.89%	60.46M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B
INNOVENT BIOLOGICS, INC.	-8.42%	8.12B

Biopharmaceuticals